JPRN-UMIN000011020
Recruiting
Phase 2
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer. - Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.
Sairtama Breast Cancer Clinical Study Group (SBCCSG)na0 sites35 target enrollmentJune 24, 2013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Advanced/recurrent HER2-positive breast cancer
- Sponsor
- Sairtama Breast Cancer Clinical Study Group (SBCCSG)na
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)having systemic infection with a fever of 38 degrees or more 2\)pleural effusion, ascites, or pericardial fluid requiring drainage 3\)brain metastasis with clinical symptoms 4\)patient with following serious complication ischaemic heart disease or heart disease such as arrhythmia not controllable by treatment myocardial infarction \< 6 months prior to study entry hepatic cirrhosis interstitial pneumonia or pulmonary fibrosis bleeding tendency 5\)having active double cancer 6\)HER2 over\-expressed 7\)pregnancy, breast\-feeding or women with childbearing potential 8\)judged by the investigator not to be appropriate for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
Completed
Phase 2
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16
Completed
Phase 2
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerJPRN-UMIN000014107SONG (South Osaka Network Group for Breast Cancer)43
Active, not recruiting
Phase 1
Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer.EUCTR2012-003505-10-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA83
Completed
Not Applicable
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35